CLINICAL PERSPECTIVE
Infective Endocarditis:
A Life-Threatening Disease
Infective endocarditis (IE) is a severe, life-threatening infection of the heart valves and the endocardial surface of the heart. For clinicians, IE represents a challenging diagnostic and therapeutic emergency, characterized by microbial colonization that leads to valvular destruction, heart failure, and systemic embolic events. Despite advances in antimicrobial therapy, the clinical burden remains high, necessitating a multidisciplinary approach and innovative mechanical solutions to stabilize the heart's architecture during the acute phase of recovery.
AI generated picture
¹ Li et al., Infective endocarditis, Lancet (2024) 404:377–92.
² Lin et al., Global, regional, and national burden of infective endocarditis from 2010 to 2021 and predictions for the next five years, BMC Public Health (2025) 25:1115.
³ Lefter, C. L., Poddi, S., & Rungatscher, A. (2025). Endocarditis: Rising incidence in the post-COVID-19 pandemic era: A narrative review. Journal of Clinical Medicine, 14(20), 7274
Age-standardized prevalence rates (ASPR) of infective endocarditis (IE) in 2021** with a mortality rate of 30%
13.8 per 100,000 ¹
Incidence with growing tendency
+40.1% ²
Global cases rose (2010-2021)
1.090.527 ³
Total cases in 2019
AI generated picture
Addressing the Innovation Gap
The treatment of infective endocarditis remains a formidable task for clinicians. Standard medical therapy consisting of 4-6 weeks of intravenous antibiotics often fails to prevent valvular destruction. When surgery is required for half of all cases, traditional implants pose long-term risks, including secondary infections and the permanent presence of foreign material in a vulnerable cardiac environment.
MitraMag addresses these critical limitations through a pioneering dual-component bioresorbable design. By providing necessary structural support during the healing phase and then undergoing complete bioresorption, our technology eliminates long-term device complications. The antimicrobial matrix shell offers an active defense against biofilm formation, filling a vital void in cardiovascular innovation.